<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088318</url>
  </required_header>
  <id_info>
    <org_study_id>OQL011B002</org_study_id>
    <nct_id>NCT04088318</nct_id>
  </id_info>
  <brief_title>A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients</brief_title>
  <acronym>NOVA-II</acronym>
  <official_title>A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OnQuality Pharmaceuticals (USA) LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OnQuality Pharmaceuticals (USA) LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial
      Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients. The main purpose of this
      study is to evaluate the safety and efficacy of OQL011 compared to vehicle ointment in
      treating patients with moderate to severe VEGFRi-associated HFSR. This study will also
      identify an optimal dosage for Phase III study and explore the pharmacokinetics profile of
      OQL011 in HFSR patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who achieve NCI CTCAE v5.0 - Palmar-Plantar Erythrodysesthesia (PPE) grade 0 or 1</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have improvement in HFSR severity and achieve clear (0) or almost clear (1) as measured by IGA-i (Investigator-assessed Investigator's Global Assessment) scale</measure>
    <time_frame>3 weeks and 6 weeks</time_frame>
    <description>The IGA scale ranges from grade 0 (clear) to 4 (severe), the higher the score, the worse the condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieve NCI CTCAE v5.0 - PPE grade 0 or 1</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HF-QoL (Hand-Foot Skin Reaction and Quality of Life) Questionnaire total score</measure>
    <time_frame>3 weeks and 6 weeks</time_frame>
    <description>HF-QoL questionnaire is comprised of a 20-item symptom domain and an 18-item daily activity domain. Each item is rated on a 5-point scale from 0 (not at all) to 4 (always or extremely) during the previous week. The HF-QoL symptom and daily activity total scores are transformed to a scale of 0 to 100, based on the sum of each unit-weighted item score divided by the maximum score. Higher scores on the HF-QoL indicate worse quality of life or greater symptom burden. (refer to R. T. Anderson et al., The Oncologist 2015;20:831-838)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient reported pain using VAS (Visual Analog Scale)</measure>
    <time_frame>3 weeks and 6 weeks</time_frame>
    <description>The subject records pain associated with HFSR using 100 mm VAS ranging from &quot;no pain&quot; at 0 mm to &quot;unbearable pain&quot; at 100 mm on the paper VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have improvement in HFSR severity and achieve clear (0) or almost clear (1) as measured by IGA-c (Centrally-assessed Investigator's Global Assessment) scale</measure>
    <time_frame>3 weeks and 6 weeks</time_frame>
    <description>The IGA scale ranges from grade 0 (clear) to 4 (severe), the higher the score, the worse the condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment by type, incidence and intensity of adverse events</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of active compound and its derivatives</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Hand-Foot Skin Reaction (HFSR)</condition>
  <arm_group>
    <arm_group_label>OQL011 Dose I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OQL011, Dose I, ointment, to be applied topically, three times a day, for up to six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OQL011 Dose II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OQL011, Dose II, ointment, to be applied topically, three times a day, for up to six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OQL011 Dose III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OQL011, Dose III, ointment, to be applied topically, three times a day, for up to six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Ointment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vehicle ointment, to be applied topically, three times a day, for up to six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OQL011</intervention_name>
    <description>OQL011 is an ointment containing active ingredient.</description>
    <arm_group_label>OQL011 Dose I</arm_group_label>
    <arm_group_label>OQL011 Dose II</arm_group_label>
    <arm_group_label>OQL011 Dose III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Ointment</intervention_name>
    <description>Vehicle ointment is an ointment containing no active ingredient.</description>
    <arm_group_label>Vehicle Ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be age ≥ 18 years.

          -  Patient must have a confirmed cancer diagnosis for which VEGFRi treatment is
             indicated, and must be currently under VEGFRi-based anti-cancer therapy with stable
             dosage for ≥ 1 week. This treatment may be VEGFRi monotherapy or VEGFRi-based
             combination therapy, so long as it does not include prohibited therapies.

          -  Patient must have shown signs of HFSR that meet the NCI CTCAE v5.0 - PPE grade 2 or
             higher.

          -  Patient on pain medications is allowed provided they have been on stable dosage in the
             past 1 week and is going to continue at the same dosage.

          -  Patient is able to use topical medications and complete questionnaires reliably.

          -  Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2.

          -  Patient must have the ability to understand and the willingness to sign a written
             informed consent prior to study entry.

        Exclusion Criteria:

          -  Patient with unresolved hand or foot skin disorders (NCI CTCAE v5.0 grade 2 or higher)
             due to other medications within 4 weeks prior to study entry.

          -  Patient who is using other topical medications in the hands or feet area and cannot
             stop such usage &gt;7 days ahead of randomization.

          -  Patient who is using other concurrent cancer medications, such as capecitabine,
             pegylated liposomal doxorubicin, 5-fluorouracil, dabrafenib, vemurafenib, doxorubicin,
             docetaxel, cytarabine, ramucirumab and bevacizumab, which may result in hand-foot
             syndrome (HFS).

          -  Patient who is under uncontrolled intercurrent illness including, but not limited to,
             inadequately controlled nausea, vomiting, diarrhea or other conditions which may
             contribute to hypovolemia, ongoing or active infection, symptomatic congestive heart
             failure, unstable angina pectoris, recent myocardial infarction, uncontrolled
             hypotension or hypertension, cardiac arrhythmia, or psychiatric illness and social
             situations that would limit compliance with study requirements.

          -  Patient who has contraindication with the active compound, including severe anemia,
             increased intracranial pressure, known hypersensitivity.

          -  Patient who has other skin disorders that will affect the efficacy evaluation on hands
             and feet area, including but not limited to, tinea of feet and hands, hand/foot
             eczema, palmoplantar pustulosis, palmoplantar keratosis, acrodermatitis continua etc.

          -  Patient who used phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil,
             vardenafil, and tadalafil within past 7 days.

          -  Patient with significantly abnormal lab test:

               -  Inadequate hematologic function as indicated by:

                    -  Absolute neutrophil counts (ANC) ≤ 1,000 /mm^3

                    -  Hemoglobin (Hgb) ≤ 8.0 g/dL

                    -  Platelet count ≤ 75,000 /mm^3

                    -  PT or PTT &gt; 1.5 x ULN (if patients on anticoagulants: PT INR &gt; 3.5 x ULN)

               -  Inadequate renal and liver function as indicated by:

                    -  Albumin &lt; 2.8 g/dL

                    -  Total bilirubin ≥ 1.5 x ULN (or ≥ 2.5 x ULN for patients with Gilbert's
                       syndrome)

                    -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and
                       alkaline phosphatase ≥ 3 x ULN (or ≥ 5 x ULN for patients with liver cancer)

                    -  Creatinine &gt; 2.0 x ULN.

          -  Pregnant or nursing women.

          -  Women of childbearing potential who are unwilling to comply with contraceptive
             requirements. Highly effective contraception which include two forms of birth control
             method (i.e., a hormonal method plus a barrier method) is advised for at least 2 weeks
             prior to study treatment and during study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario E. Lacouture, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Tang, MD</last_name>
    <phone>+1-224-251-9794</phone>
    <email>Hong.Tang@OnQualityRx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johnny Ju, MSc</last_name>
    <phone>+86-137-6163-6367</phone>
    <email>Juegang.Ju@OnQualityRx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino, CCRP</last_name>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Eric M. Cheung, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robyn Swing, CCRP</last_name>
      <email>robyn.swing@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Elaine T. Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Rangel, PhD, CCRP</last_name>
      <email>stephanie.rangel@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer N. Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville - Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Healey, CCRC</last_name>
      <email>mary.healey@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Robert C. Martin, MD,PhD,FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Tabacchi</last_name>
      <email>mtabacchi@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Milan J. Anadkat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Health St. Francis - Hospital</name>
      <address>
        <city>Hastings</city>
        <state>Nebraska</state>
        <zip>68901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Gulzow</last_name>
    </contact>
    <investigator>
      <last_name>Ryan C. Ramaekers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino, CCRP</last_name>
      <email>kbettino@airesearch.us</email>
    </contact>
    <investigator>
      <last_name>Gilbert M. Nyamuswa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alana Deutsch</last_name>
      <email>alana.deutsch@einsteinmed.org</email>
    </contact>
    <investigator>
      <last_name>Beth N. Mclellan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabrina Trelles</last_name>
      <email>trelless@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Mario E. Lacouture, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University - Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppina Caravella, MPH</last_name>
      <email>giuseppina.caravella@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Yue Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Dermatology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leah Kofmehl</last_name>
      <email>Leah.Kofmehl@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin H. Kaffenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Chan</last_name>
      <email>CChan2@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Anisha B. Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data (IPD) available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

